Risperidone in the treatment of childhood autistic disorder: An open pilot study

Acta Neuropsychiatrica

Volumn 14, Issue 5, 2002, Pages 242-249

  Casaer, Paul ^a   Croonenberghs, J A N ^b,c   Lagae, Lieven ^a   Deboutte, Dirk ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Autism; Behavioral disturbances; Extrapyramidal symptoms; Mental retardation; Risperidone

Indexed keywords

RISPERIDONE;

ABSENCE; ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; INSOMNIA; LIVER TOXICITY; MALE; MONOTHERAPY; MULTICENTER STUDY; RATING SCALE; RHINITIS; SYMPTOMATOLOGY; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN;

EID: 0036812225     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-5215.2002.140508.x     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. (DSM-IV). Washington, DC: American Psychiatric Association, 1994:66-71.
2. Demyer MK, Hingtgen JN, Jackson RK. Infantile autism reviewed. A decade of research. Schizophr Bull 1981;7:388-451.
3. Volkmar FR, Cohen DJ. Current concepts. Infantile autism and the pervasive developmental disorders. J Dev Behav Pediatr 1986;7:324-329.
4. Tsai LY. Medical treatment in autism. In: Berkell DE, ed. Autism: Identification, Education and Treatment. Hillside, New Jersey: Erlbaum, 1992:151-184.
5. Croonenberghs J, Deboutte D, Maes M. Pathophysiology of autism: Current opinions. Acta Neuropsychiatrica 2001;00:000-000.
6. Gilman JT, Tuchman RF. Autism and associated behavioral disorders: Pharmacotherapeutic intervention. Ann Pharmacother 1995;29:47-56.
7. Campbell M, Cueva JE. Psychopharmacology in child and adolescent psychiatry: A review of the past seven years. Part I. J Am Acad Child Adolesc Psychiatry 1995;34:1124-1132.
8. Locascio JJ, Malone RP, Small AM et al. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 1991;27:119-126.
9. Whitaker A, Rao U. Neuroleptics in pediatric psychiatry. Psychiatr Clin North Am 1992;15:243-276.
10. Panksepp J. A neurochemical theory of autism. Trends Neurosci 1979;2:174-177.
11. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995;34:223-231.
12. Gillberg C. Endogenous opioids and opiate antagonists in autism: Brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 1995;37:239-245.
13. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, van Engeland H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind, placebo-controlled studies. Arch General Psychiatry 1995;52:766-773.
14. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatr Res 1995;58:203-215.
15. Anderson GM, Freedman DX, Cohen DJ et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry Allied Discip 1987;18:885-900.
16. Anderson GM, Horne WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. Ann NY Acad Sci 1990;600:331-340.
17. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch General Psychiatry 1993;50:441-447.
18. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-745.
19. Piggott LR, Gdowski CL, Villaneuva D, Fischhoff J, Frohman CF. Side-effects of fenfluramine in autistic children. J Am Acad Child Psychiatry 1986;25:287-289.
20. Deutsch SI, Campbell M. Relative affinities for different classes of neurotransmitter receptors predict neuroleptic efficacy in infantile autism: A hypothesis. Neuropsychobiol 1986;15:160-164.
21. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
22. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 1997;58:538-546.
23. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995;166:712-726.
24. Lemmens P, Dedeyn PP, Desmedt G. Risperidone in the treatment of behavioral disturbances in dementia. Presented at the Annual Meeting of the American Psychiatric Association, Toronto (Ontario), May 30-June 4, 1998.
25. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
26. Purdon SE, Lit W, Labelle A, Jones BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-405.
27. Simeon JG, Carrey NJ, Wiggins DM, Milin RP, Hosenbocus SN. Risperidone effects in treatment-resistant adolescents: Preliminary case reports. J Child Adol Psychopharmacol 1995;5:69-79.
28. Croonenberghs J. Risperdal in the treatment of 4 children with a DSM-III R Axis 2 diagnosis: 'Autistic Disorder' without concomitant diseases. Poster presented at the 5th International Congress of Autism Europe, Barcelona (Spain), May 1996.
29. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997;331:155-159.
30. Malone RP, Rowan AB, Blaney BL, Biescker KA, Delaney MA. Open risperidone in pervasive developmental disorder. Psychopharmacol Bull 1997;333:553.
31. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-693.
32. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-641.
33. Mandoki MW. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side-effects? J Child Adolesc Psychopharmacol 1995;5:49-67.
34. Baldessarini RJ, Teicher MH. Dosing of antipsychotic agents in pediatric populations. J Child Adolesc Psychopharmacol 1995;5:1-4.
35. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms for patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 1986;25:130-136.
36. Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist. A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-491.
37. Aman MG, Richmond G, Stewart AW, Bell JC, Kissel RC. The Aberrant Behavior Checklist. Factor structure and the effect of subjective variables in American and New Zealand facilities. Am J Ment Defic 1987;91:570-578.
38. Guy W. The clinical global impression. In: ECDU Assessment Manual for Psychopharmacology (Revised). Rockville (Maryland): National Institute of Mental Health. DHEW publication (ADM). 1976:76-330.
39. Lippert HJ, Lehmann JP. SI Units in Medicine. Baltimore: Urban and Schwarzenberg, 1978.